Zevra Therapeutics (ZVRA) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.25
- Estimate
- $0.16
- Surprise
- +56.3%
- Revenue (period 2026-06-30)
- $39.7M
- Score today
- 7.6/10
Revenue source: xbrl.
How the report landed
Zevra Therapeutics (ZVRA) beat the $0.16 estimate with adjusted EPS of $0.25 — a large 56.3% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates ZVRA Buy (Wait) at 7.6/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +56.3% surprise compares with a +130.7% four-quarter average. Next scheduled report: 2027-03-08.
What supports the rating
- Strong earnings beat streak (4/4)
- Strong overall score: 7.6/10
What argues against it
- Concentration risk — Product: MIPLYFFA (82.0%)
- Negative momentum
- Elevated risk factors
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $9.25
- Entry target
- $8.72
- Price target
- $20.01
- Stop
- $8.11
- Upside to target
- +116.3%
- Reward-to-risk
- 7.8:1
Forward estimates sit below the trailing run-rate (10.2× forward vs 7.4× trailing) — consensus expects earnings to decline from here.
Risk check: trading volume is running 1.6× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-11-17 — shown for context, not personalized investment advice.
ZVRA at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $540.3M
- P/E (fwd)
- 10.2
- P/E (ttm)
- 7.4
- 52-week range
- $8.01–$15.04
- Off 52-week high
- 38.5%
- RSI (14)
- 44
- Volume vs avg
- 1.59×
- Score today
- 7.6/10